Summary
12.68 -0.99(-7.21%)05/17/2024
CryoPort Inc (CYRX)
CryoPort Inc (CYRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.72 | 1.55 | -11.86 | 5.66 | 58.29 | -25.99 | 2.82 | -97.81 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.43 | |
| Open | 16.03 | |
| High | 16.89 | |
| Low | 15.90 | |
| Volume | 477,089 | |
| Change | 0.44 | |
| Change % | 2.72 | |
| Avg Volume (20 Days) | 284,498 | |
| Volume/Avg Volume (20 Days) Ratio | 1.68 | |
| 52 Week Range | 9.00 - 24.17 | |
| Price vs 52 Week High | -32.02% | |
| Price vs 52 Week Low | 82.56% | |
| Range | 2.50 | |
| Gap Up/Down | -0.62 | |
Fundamentals | ||
| Market Capitalization (Mln) | 623 | |
| EBIDTA | -41,327,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 17.89 | |
| Book Value | 9.0120 | |
| Earnings Per Share | -2.4800 | |
| EPS Estimate Current Quarter | -0.3500 | |
| EPS Estimate Next Quarter | -0.3300 | |
| EPS Estimate Current Year | -1.4200 | |
| EPS Estimate Next Year | -1.1000 | |
| Diluted EPS (TTM) | -2.4800 | |
| Revenues | ||
| Profit Marging | -0.5018 | |
| Operating Marging (TTM) | -0.3898 | |
| Return on asset (TTM) | -0.0439 | |
| Return on equity (TTM) | -0.2187 | |
| Revenue TTM | 225,030,000 | |
| Revenue per share TTM | 4.6020 | |
| Quarterly Revenue Growth (YOY) | -0.1310 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 103,873,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 58.1395 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.8593 | |
| Revenue Enterprise Value | 3.6265 | |
| EBITDA Enterprise Value | -12.7475 | |
| Shares | ||
| Shares Outstanding | 49,257,400 | |
| Shares Float | 44,719,848 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.10 | |
| Insider (%) | 2.42 | |
| Institutions (%) | 107.78 | |
05/18 11:00 EST - accesswire.com
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/17 11:00 EST - accesswire.com
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/16 11:15 EST - accesswire.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/15 13:15 EST - accesswire.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/07 21:50 EST - seekingalpha.com
Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight – KeyBanc Yuan Zhi – B. Riley David Saxon – Needham Operator Good afternoon and welcome to Cryoport Fourth Quarter and Full Year 2023 Earnings Conference Call.
Cryoport, Inc. (CYRX) Q1 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Todd Fromer – Investor Relations-KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President-Corporate Development and Investor Relations Conference Call Participants Matt Stanton – Jefferies Philip Song – Leerink Partners Lucas Baranowski – UBS David Larsen – BTIG Paul Knight – KeyBanc Yuan Zhi – B. Riley David Saxon – Needham Operator Good afternoon and welcome to Cryoport Fourth Quarter and Full Year 2023 Earnings Conference Call.
05/07 16:08 EST - prnewswire.com
Cryoport Reports First Quarter 2024 Financial Results
Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675 global clinical trials supported as of March 31, 2024 $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tenn. , May 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024.
Cryoport Reports First Quarter 2024 Financial Results
Q1 2024 revenue of $54.6 million 9% year-over-year increase in Commercial Cell & Gene Therapy revenue 9% year-over-year increase in BioStorage/BioServices revenue A total of 675 global clinical trials supported as of March 31, 2024 $242 - $252 million full year 2024 revenue guidance reiterated NASHVILLE, Tenn. , May 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024.
05/07 13:30 EST - accesswire.com
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cryoport, Inc. and Encourages Investors to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
04/30 08:30 EST - prnewswire.com
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024
NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close.
Cryoport to Report First Quarter 2024 Financial Results on May 7, 2024
NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close.
04/25 11:06 EST - zacks.com
Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
CryoPort (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: CryoPort, Inc. (CYRX) Q1 Earnings Expected to Decline
CryoPort (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
03/12 20:48 EST - seekingalpha.com
Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
Cryoport, Inc. (CYRX) Q4 2023 Earnings Call Transcript
03/12 18:31 EST - zacks.com
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago.
CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.24 per share a year ago.
03/12 16:05 EST - prnewswire.com
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
FY 2023 revenue of $233.3 million, in-line with guidance Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% Global clinical trials supported reached a record 675 NASHVILLE, Tenn., March 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
FY 2023 revenue of $233.3 million, in-line with guidance Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45% Global clinical trials supported reached a record 675 NASHVILLE, Tenn., March 12, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for cell & gene therapies, today announced financial results for the fourth quarter (Q4) and year (FY) ended December 31, 2023.
02/27 08:30 EST - prnewswire.com
Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.
Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2023 on Tuesday, March 12, 2024 after U.S. markets close.
02/15 11:06 EST - zacks.com
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out for
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.